Perpetuating the Pharmaceutical Pipeline

Dzinkowski, Ramona
September 2003
Financial Executive;Sep2003, Vol. 19 Issue 6, p21
Academic Journal
An interview with Charles Golden is presented. When asked about growth in the pharmaceutical industry, Golden notes that many mergers in the industry occurred out of weakness. When asked how to deal with the lengthy response times needed to test new drugs, Golden discusses how his companies portfolio is constantly updated. When to name a new technology aimed at shortening the development time of new drugs, Golden discusses how Internet forums where doctors share information are valuable.


Related Articles

  • Proposal of Adaptability Indexes to Support Management of Engineering and Marketing Systems. Agostinho, Oswaldo Luiz // Proceedings of the European Conference on Information Management;2012, p1 

    The Responsiveness of Productive Systems has become a prerequisite to meet the demands of high diversification of products being manufactured simultaneously, coupled with the reduction of lot sizes and the reduction of life cycle of those products. Organizations that have portfolios with large...

  • Sourcing By Design: Product Complexity and the Supply Chain. Novak, Sharon; Eppinger, Steven D. // Management Science;Jan2001, Vol. 47 Issue 1, p189 

    This paper focuses on the connection between product complexity and vertical integration using original empirical evidence from the auto industry. A rich literature has address the choice between internal production and external sourcing components in the auto industry. More recent literature...

  • Unraveling the ramifications of recent pharmaceutical industry acquisitions by looking at the... Herzfeld, Jeffrey D. // Employee Benefits Journal;Mar1995, Vol. 20 Issue 1, p20 

    Resolves the ramifications of pharmaceutical industry acquisitions by reviewing the pharmacy benefit management firms (PBMs). Acquisition of PBMs by drug manufacturers; Disease management; Operational modes of PBMs; Management of cost of prescription drugs; Effect of legislation on PBMs and...

  • Drug wholesaler buys rival.  // Drug Topics;7/21/97, Vol. 141 Issue 14, p8 

    Reports that Neuman Health Services company acquired the Drug Guild Distributors company. Background information on both companies; Benefits of the acquisition to Drug Guild.

  • Wholesaler mergers may be conditional.  // Drug Topics;2/16/98, Vol. 124 Issue 4, p7 

    Focuses on modifications to be made to two proposed megamergers in the wholesale drug industry in the United States. Identification of the companies proposing the mergers; Percentage of the market the merged companies will control; Reference to federal approval of these proposed mergers.

  • More drug companies expected to combine.  // Indianapolis Business Journal;7/22/96, Vol. 17 Issue 18, p13A 

    Focuses on mergers in the drug industry. Economic pressure; Possible combinations; Pricing concerns; Comments from industry executives. INSET: Prozac sales disappointing, analysts say..

  • Drug mergers show companies' lack of confidence. Schrage, Michael // Inside Tucson Business;2/13/95, Vol. 4 Issue 46, p7 

    Focuses on the merger of companies in the pharmaceutical industry in the United States. Lack of confidence that research and development process can sustain business; Offer by Glaxo to acquire Wellcome for 14 billion dollars; Goal to apply new technologies that will reduce the costs of drug...

  • U.S. district court blocks mergers of drug wholesalers.  // hfm (Healthcare Financial Management);Sep98, Vol. 52 Issue 9, p21 

    Reports that the United States District Court for the District of Columbia has blocked two proposed mergers involving the nation's four largest drug wholesalers. Court's agreement with the Federal Trade Commission's position that the mergers would have had an anticompetitive effect; Mergers'...

  • Is bigger better? Drugmakers reorder for a new future. Taylor, Kathryn S. // H&HN: Hospitals & Health Networks;10/20/94, Vol. 68 Issue 20, p94 

    Describes the effect of consolidations in the pharmaceutical industry on health care providers in the United States. Acquisitions and mergers; Advantages of the mergers; Effect of managed care on the pharmaceutical industry's control over the law of supply and demand; Benefits on hospitals and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics